The human proton-dependent dipeptide transporter (PEPT1, gene SLC15A1) is important for intestinal absorption of di-and tripeptides and a variety of peptidomimetic compounds. Using a DNA polymorphism discovery panel of 44 ethnically diverse individuals, nine nonsynonymous and four synonymous coding-region single-nucleotide polymorphisms (SNPs) were identified in PEPT1. HeLa cells were transiently transfected with plasmids constructed by site-directed mutagenesis for each of the nine nonsynonymous variants. Quantitative polymerase chain reaction showed that the mRNA transcription level of all of the mutants was comparable with the mRNA transcription level of the reference sequence in transfected HeLa cells. Functional analysis in transiently transfected HeLa cells revealed that all nonsynonymous variants retained similar pH-dependent activity and K t values for [glycyl-1,2-14 C]glycylsarcosine (GlySar) uptake as the reference PEPT1. In addition, a group of seven peptide-like drugs showed inhibitory effect on Gly-Sar uptake by these variants comparable with the reference, suggesting conserved drug recognition. Of the nine nonsynonymous SNPs, a single SNP (P586L) demonstrated significantly reduced transport capacity as evidenced by a much lower V max value. This was consistent with lower immunoactive protein level (Western analysis) and lower plasma membrane expression (immunocytochemical analysis). Therefore, Pro 586 may have profound effect on PEPT1 translation, degradation, and/or membrane insertion.
In recent years, molecular characterization of numerous drug transporters has greatly expanded our understanding of cellular mechanisms of drug disposition. By controlling the cellular entry and exit of compounds, drug transporters have been recognized as important determinants of drug absorption, distribution, and elimination. In the small intestine, nutrient transporters, such as the intestinal peptide transporter, are involved in the active absorptive influx of xenobiotics (i.e., ␤-lactam antibiotics) from the intestinal lumen to the portal blood (Dantzig, 1997) . In opposition to compound influx, P-glycoprotein is responsible for the active efflux of drugs (i.e., digoxin) from intestinal epithelial cells back to the lumen (Sababi et al., 2001 ). In the liver, there is a large set of influx and efflux transporters that play important roles in the clearance and excretion of drugs. For example, pravastatin (Tokui et al., 1999 ) is extracted efficiently from portal vein by the liver through the organic anion transporting polypeptide C (OATP-C). In the kidney, antiviral reagents such as adefovir and cidofovir can undergo active secretion by the organic anion transporter (Ho et al., 2000) .
Genetic variations in the enzymes responsible for phase I and II metabolism have been shown to be a source of interindividual variability in drug effect and disposition (Meyer and Zanger, 1997; Hayes and Strange, 2000; Mackenzie et al., 2000; Rodrigues and Rushmore, 2002) . Therefore, it is not surprising that genetic variations in drug transporter genes have been also implicated in changes of transporter expression level and function, which could affect drug disposition (Hoffmeyer et al., 2000; Ito et al., 2001; Tirona et al., 2001; Leabman et al., 2002) . For example, alterations in the disposition of fexofenadine ) and digoxin (Hoffmeyer et al., 2000) were found linked to polymorphisms in P-glycoprotein. Most recently, it has been shown that one commonly occurring SNP (T521C) in the OATP-C is likely to be related to altered pharmacokinetics of pravastatin in a Japanese population (Nishizato et al., 2003) .
The intestinal proton-dependent dipeptide transporter PEPT1 was first cloned from rabbit (Fei et al., 1994) and subsequently from human, mouse, and rat (Liang et al., 1995; Saito et al., 1995; Fei et al., 2000) . The nucleotide and primary amino acid sequence of PEPT1 is highly homologous across species and has a high transport capacity in small intestine. In addition to its naturally occurring substrates, di-and tripeptides, PEPT1 is capable of actively transporting a variety of chemically diverse compounds, including ␤-lactam antibiotics, renin inhibitors, and angiotensin-converting enzyme inhibitors (Rubio-Aliaga and Daniel, 2002) . Because of the broad substrate specificity of PEPT1, a prodrug approach, by which a poorly bioavailable drug is modified to be transported by PEPT1, has been intensively investigated as a promising strategy to improve oral absorption of certain molecules (Balimane et al., 1998; Steffansen et al., 1999; Friedrichsen et al., 2001; Thomsen et al., 2003) . It is anticipated that with the unfolding of substrate structural requirements of PEPT1, more rationally designed peptidomimetic molecules and prodrugs targeting to PEPT1 will be generated in the future.
Despite increasing efforts in investigating PEPT1 as a possible drug delivery system for small peptides and peptidelike compounds, little information is available regarding potential functional consequence of genetic variations of human PEPT1. In the present study, we identified 13 cSNPs in PEPT1 using a DNA polymorphism discovery panel and studied their function in vitro. We show that all PEPT1 nonsynonymous variants identified in this study have conserved substrate recognition. In addition, one variant (P586L) was associated with profound reduction in uptake capacity.
Materials and Methods
Materials. [glycyl-1,2- 14 C]Glycylsarcosine (Gly-Sar) (110 mCi/ mmol) was purchased from Moravek Biochemicals (Brea, CA). Bicinchoninic acid protein assay kit was purchased from Pierce Chemical (Rockford, IL). Rabbit anti-human PepT1 polyclonal antiserum was custom-made by Zymed Laboratories (South San Francisco, CA) and prepared from animals injected with a peptide corresponding to the last 16 amino acid residues of human PEPT1 (KSNPYFMS-GANSQKQM). Rabbit anti-calnexin polyclonal antibody was from Stressgen (Victoria, BC, Canada). Unlabeled Gly-Sar, glycine, cefadroxil, captopril, cephalexin, enalapril, L-3,4-dihydroxyphenyl alanine (L-DOPA), bestatin, and 5-aminolevulinic acid hydrochloride were from Sigma-Aldrich (St. Louis, MO). HeLa cells (CCL-2) were obtained from the American Type Culture Collection (Manassas, VA). Cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 4.5 g/l glucose, 110 mg/l sodium pyruvate, 584 mg/l L-glutamine, 0.1 mM nonessential amino acids, 100 units/ml penicillin, and 100 g/ml streptomycin (Invitrogen, Carlsbad, CA) at 37°C in a humidified atmosphere with 5% CO 2 .
SNP Identification. PEPT1 mRNA sequence was obtained from GenBank (accession no. NM_005073). This sequence was designated as the reference PEPT1 in the study. Determination of coding sequence, untranslated regions and intronic regions was based on annotation in the GenBank databases. Samples used for polymorphism discovery were obtained from a DNA polymorphism discovery panel (M44PDR) from Coriell Cell Repositories (Camden, NJ). The panel consists of genomic DNA isolated from 44 unrelated individuals of different ethnicity, including 11 European-American, 11 African-American, 11 Asian-American, six Mexican-American, and five native Americans.
PCR assays were designed to obtain a product of ϳ500 bp that includes 50 -80 bp of flanking intronic sequence. The genomic PCR reaction was carried out with DNA polymerase AmpliTaq Gold (Applied Biosystems, Foster City, CA). A 25-l PCR reaction was performed containing 100 ng of genomic DNA, 1 unit of AmpliTaq Gold, 2.5 pmol of forward primer, 2.5 pmol of reverse primer, 0.2 mM dNTPs, 1ϫ AmpliTaq Gold buffer, and 4% dimethyl sulfoxide. The reaction mixture was denatured at 94°C for 3 min, followed by 12 touchdown cycles [94°C, 30 s; 60°C (0.5°C decrease for each cycle until 55°C), 30 s; 72°C, 2 min], 35 regular cycles (94°C, 30 s; 55°C, 30 s; 72°C, 2 min), and a final incubation at 72°C for another 5 min. Aliquots (1-2 l) of unpurified PCR product were used for each sequencing reaction. The sequencing reaction was carried out from both directions using ABI Big Dye Terminator Sequencing kits on an ABI 3700 capillary analyzer (Applied Biosystems).
SNP identification was completed using the ABI sequence software for base calling. Chromatograms were transferred to a sequence assembly software-Sequencher (Gene Codes, Ann Arbor, MI). Each base call was compared with the consensus sequence, and the variants were confirmed by visual inspection of the chromatograms.
Haplotype Analysis. Genotype results of the nine cSNPs from the panel of 44 individuals were used to estimate the haplotypes constructed out of these cSNPs. Haplotypes were determined using the "Haplotyper" algorithm (Niu et al., 2002) . Specifically, the algorithm partitions the set of SNPs into smaller sets, estimating the phase for each of the smaller sets by a Gibbs sampler and then combining the adjacent sets using Gibbs sampler again to construct one level bigger haplotypes and thus continuing until the whole haplotype was estimated.
Construction of Expression Vectors for the Reference and Variant PEPT1s.
The open reading frame of the human reference PEPT1 was first amplified from human small intestine QUICK-CLONE cDNA (BD Biosciences Clontech, Palo Alto, CA) by pfuTurbo DNA polymerase (Stratagene, La Jolla, CA) and subcloned into Pcrii (Invitrogen). Then, the cDNA fragment of human PEPT1 was constructed to contain BamH1 site at 5Ј side and XbaI site at 3Ј side. Finally, the fragment was introduced into BamH1/XbaI sites of pcDNA3.1 expression vector (Invitrogen).
Point mutations were introduced into the constructed vector containing the reference PEPT1 using the QuikChange site-directed mutagenesis kit (Stratagene). Each variant PEPT1 in the vector was fully sequenced to ensure that only desired mutation was introduced.
Transfection, Uptake Study, and Western Analysis of the Reference and Variant PEPT1s. HeLa cells were seeded onto 24-well plates. When the cells reached 70 to 80% confluence, transfection was performed with FuGENE 6 (Roche Diagnostics, Indianapolis, IN) according to manufacturer's protocol. PEPT1-mediated [ 14 C]Gly-Sar uptake activity was measured in the cells cultured in 24-well plates 24-h post-transfection. The uptake medium was maintained at either pH 6.0 or 7.4 as described previously (Liang et al., 1995) . Nonspecific uptake due to passive diffusion was determined in parallel experiments in HeLa cells transfected with the empty pcDNA3.1 vector. The cells were incubated for [
14 C]Gly-Sar uptake for 3 min at room temperature. At the end of incubation, the cells were washed three times with ice-cold phosphate-buffered saline (PBS) (pH 7.4) and lysed in 0.3 ml/well of PBS with 1% Triton X-100 for 30 min. The aliquots were subjected to both liquid scintillation counting and protein quantification by the bicinchoninic acid protein assay kit. Uptake activity was determined as the number of picomoles of Gly-Sar per milligram of protein per 3 min.
To measure Gly-Sar transport kinetics, [ 14 C]Gly-Sar uptake in a concentration range of 0.094 to 3 mM was assessed with incubation time of 3 min, which is within the linear phase of the uptake process (the first 5 min). Passive diffusion (K d , diffusion coefficient) was determined in parallel experiments in HeLa cells transfected with an empty pcDNA3.1 vector. Experimental data were fitted by KaleidaGraph (Synergy Software, Reading, PA) , in which a model describing the uptake as a process combining diffusion and single site carriermediated transport (Liang et al., 1995) was used. The fitted kinetic parameters were presented as the maximal uptake velocity, V max , and the concentration, K t , when uptake rate reaches one-half of V max . All experiments were carried out in triplicate on two to three different experimental days.
For immunoblotting studies, the transfected HeLa cells were washed with PBS and lysed in lysing buffer as described previously (Wong et al., 1995) . Lysates were diluted with Laemmli sample loading buffer and separated by a 4 to 20% SDS-polyacrylamide gel. After transfer onto Immun-Blot polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA), blots were probed with anti-human PEPT1 (1:2000) or anti-calnexin (1:2000) antibodies and visualized using a biotinylated anti-rabbit IgG and a chromogenic detection system (Vector Laboratories, Burlingame, VA).
Immunocytochemical Analysis. HeLa cells were grown on the four-well Lab-Tek chambered coverglass (Nalge Nunc International, Rochester, NY) and transfected with expression vectors containing the reference or P586L variant as described above. Cells were fixed in 1% formaldehyde in PBS for 10 min, permeabilized in PBS containing 0.025% Nonidet P-40 (Sigma-Aldrich), and 1% bovine serum albumin for 15 min, and blocked with Protein Block (DakoCytomation California Inc., Carpinteria, CA) for 30 min. Cells were then incubated with the rabbit anti-human PEPT1 antibody for 1 h at room temperature, washed three times with PBS containing 1% bovine serum albumin, and incubated with Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes, Eugene, OR) at a dilution of 1:500 in the antibody diluent (DakoCytomation California Inc.) for 1 h. Finally, cells were counterstained by 0.075 mM propidium iodide (Molecular Probes, Eugene, OR) in PBS for 5 min before visualization and analysis by MRC1024-UV confocal system (Bio-Rad, Hemel Hemstead, UK).
Quantitative Real-Time PCR. The mRNA expression level of each PEPT1 variant in comparison with the reference in transiently transfected HeLa cells was measured using SYBR Green-based quantitative real-time PCR. Specifically, transfected HeLa cells were washed with PBS 24 h post-transfection, trypsinized, and collected by centrifugation. Total RNA was extracted from cells by RNeasy Mini kit (QIAGEN, Valencia, CA) according to manufacturer's protocol. Purified total RNA (8 g) was digested by BamH1 and XbaI restriction enzymes (Invitrogen) to linearize the residue plasmids post-RNA isolation, followed by DNase-I treatment (DNA-free; Ambion, Austin, TX) according to manufacturer's instructions. Firststrand cDNA was synthesized from treated RNA (1.5 g) primed with random hexamers (150 ng), using SuperScript II RNase H Ϫ reverse transcriptase (Invitrogen). Parallel control reactions were performed in the absence of reverse transcriptase (no-RT-control).
The internal standard curve was generated by using the reference PEPT1 cDNA diluted serially in diethyl pyrocarbonate-treated water, i.e., solutions of 3.75, 0.75, 0.1875, 0.0375, and 0.0075 ng of RNA-equivalent cDNA/l. All samples were diluted in diethyl pyrocarbonate-treated water to 0.75 ng of RNA-equivalent cDNA/l. PEPT1-specific primers are sense, TTCTTCTCACCTGTGGCGAAG and antisense, TTGGAAGGAGCCTGAGAATATGA. 18S rRNA was used as an endogenous control (sense, CGGCTACCACATCCAAG-GAA and anti-sense, GCTGGAATTACCGCGGCT). Real-time PCR was performed in 20-l volume containing 1ϫ SYBR Green PCR Master Mix (Applied Biosystems), 0.2 unit of AmpErase uracil Nglycosylase (Applied Biosystems), 800 nM of each PEPT1-specific primers or 500 nM of 18S rRNA-specific primers, and 3 ng of RNAequivalent of cDNA. Real-time PCR reactions were set up in a 384-well plate by a robotic liquid handling system (Tecan U.S., Durham, NC). The expression levels of PEPT1 and 18S rRNA of each sample and standards were measured in separate amplification reactions in five replicates using an ABI Prism 7900HT sequence detection system (Applied Biosystems) under the following cycling parameters: 50°C, 2 min; 95°C, 10 min; 40 cycles of 95°C, 15 s; and 60°C, 1 min. Sample of no-template-control and no-RT-control were also included in the sample 384-well plate. Each amplification included an endpoint melting curve analysis (60°C, 15 s; 2% temperature ramp to 95°C, 15 s) to identify nonspecific amplification products (dissociation curve analysis).
Relative starting quantity of PEPT1 gene and 18S rRNA in each experimental sample was calculated from the standard curve method (Heid et al., 1996) . Postamplification, initial quantity of each cDNA was obtained by plotting cycle threshold (C t ) versus quantity against known quantities of the standards. A mean of five identical replicates was used to calculate a single quantity value. The SEM of the replicate wells was calculated for each PEPT1 sample and 18S rRNA. The relative expression level of each PEPT1 sample was calculated by normalizing the mean quantity of PEPT1 to the mean quantity of the 18S rRNA value. An overall SEM (␦) was derived using the delta method as described previously (Bishop et al., 1975) :
where m x is the mean of PEPT1 quantity; m y is the mean of 18S rRNA quantity; SEM x is the SEM of PEPT1; and SEM y is the SEM of 18S rRNA.
Results
Coding-Region Single-Nucleotide Polymorphisms in PEPT1. Upon screening a DNA polymorphism discovery panel comprising 44 individuals with different ethnicity, four synonymous and nine nonsynonymous cSNPs in human PEPT1 gene were identified (Table 1) . Genotyping raw data of the 44 individuals is available online as a data supplement to this article. According to a putative PEPT1 membrane topology model (Fig. 1) , most mutations occur on the extracellular loops, and two of nonsynonymous SNPs are in the putative transmembrane regions. Many of these amino acids are highly conserved among PEPT1 orthologs and human PEPT2 (Fig. 2) .
Haplotype analysis was conducted on the nine nonsynonymous cSNPs identified in this study. The estimated haplotypes are summarized in Fig. 3 . Ten haplotypes were deduced. The dominant (Ͼ62%) haplotype is the one corresponding to the reference PEPT1 gene. The other haplotypes with relatively high estimated incidence are S117N (22.7%) and G419A (6.8%). The rest of haplotypes include some variants with double or Each PEPT1-related C t value from the no-RT-control RNA sample was sufficiently higher (Ͼ9) than values obtained from each sample and thus was not considered interfering with RNA analysis (data not shown). 18S rRNA expression level was invariable among different samples (Ct average was 9.17 Ϯ 0.22). As shown in Fig. 4 , the mRNA level of each variant ranged from 1.6-to 2.2-fold of the reference level.
Functional Analyses of PEPT1 Variants in Transfected HeLa Cells. Using site-directed mutagenesis, expression vectors containing each PEPT1 variant were constructed. When transiently expressed in HeLa cells, the reference PEPT1 transported Gly-Sar in a pH-dependent manner (Fig. 5A ). This pH-dependent uptake was seen with the other variants, all of which transported Gly-Sar at a higher rate at pH 6.0 than at pH 7.4. Under the conditions used in this experiment, uptake rate of R459C was similar to the reference value, whereas uptake rates of the other variants (except for P586L) ranged from 1.3-to 1.6-fold of the reference value. Most distinctively, P586L showed a greatly reduced uptake rate (p Ͻ 0.01; Fig. 5A ).
Both anti-PEPT1 and anti-calnexin antibodies were used in Western blot studies. The anti-PEPT1 antibody detected PEPT1-specific bands (ϳ75 to ϳ100 kDa) in the cell extract from PEPT1 reference and variants (Fig. 5B) , but not from the mock-transfected cells. In addition, it is evident that the immunoreactive protein level of P586L was lower than those of the reference and the other variants, compared with the loading baseline provided by calnexin (Fig. 5C) , which has been shown to be consistently expressed in transfected HeLa cells (Alvarez et al., 2003 ). This reduction in protein level seems consistent with the considerably diminished uptake rate of P586L (Fig.  5A) .
As shown in Fig. 6 , the same anti-PEPT1 antibody was used to detect PEPT1 expression in immunocytochemical analysis. The amplified green fluorescent signal was observed mostly on the cell membrane of transfected HeLa cells (Fig. 6 , B and C), whereas some nonspecific cytoplasmic staining could be observed with mock-transfected cells (Fig.  6A) . Moreover, the level of plasma membrane expression of the reference PEPT1 (Fig. 6B ) seemed much higher than that of the P586L variant (Fig. 6C ). These data, again, are in good agreement with the lower immunoreactive protein level of P586L (Fig. 5B) as well as its diminished uptake rate (Fig.  5A) .
For a more comprehensive functional characterization, the concentration-dependent kinetics of Gly-Sar uptake was assessed for each PEPT1 variant. Determined by nonlinear curve fitting, the kinetic parameters are summarized in Table 2. All variants possessed K t and V max values similar to the reference, except for P586L, which retained a comparable K t value, but had an approximately 10-fold lower V max value (p Ͻ 0.01) than the reference and other variants.
For a further characterization of substrate recognition of each variant, seven previously reported PEPT1 drug substrates (Rubio-Aliaga and Daniel, 2002) were used to test relative inhibitory effects on Gly-Sar uptake by each variant (Table 3) . Glycine (negative control, 10 mM) showed minimal inhibition on [ 14 C]Gly-Sar uptake by PEPT1 reference and variants, whereas unlabeled Gly-Sar (positive control, 10 mM) achieved nearly complete inhibition. The inhibition on Gly-Sar uptake by the reference and variants was similar for most drug substrates as demonstrated by the percentage of inhibition. To be specific, for bestatin, 5-aminolevulinic acid hydrochloride, and enalapril, each compound inhibited GlySar uptake by all variants and the reference to a relatively high extent; for cefadroxil, captopril, and cephalexin, each showed medium inhibitory effect on all variants and the reference; L-DOPA was the weakest inhibitor for all variants and the reference. Therefore, based on this information, we conclude that the selected seven drug substrates for human PEPT1 (reference) are likely to be substrates of all the PEPT1 variants, and the recognition of these drug substrates seems to be conserved among PEPT1 reference and variants.
To examine the phenotype of PEPT1 haplotypes, we also constructed the expression plasmids corresponding to the estimated haplotypes containing double or triple mutations (Fig. 3) , i.e., S117N/T451N, S117N/G419A/R459C, S117N/ V416L, and S117N/V122M/G419A. These double-or triplealtered variants retained similar pH-dependent Gly-Sar uptake as the reference and those of the variants with the single amino acid changes (data not shown). These data suggest 
Discussion
Recently, a set of 24 membrane transporter genes was selected by the Pharmacogenetics of Membrane Transporters (PMT) project to be examined for genetic polymorphisms (Leabman et al., 2003) . As a result, preliminary sequence information on some genetic variations of PEPT1 became public (www.pharmgkb.org); however, no functional data are available, and little can be surmised regarding whether these PEPT1 polymorphisms could lead to interindividual variability in oral absorption of PEPT1 drug substrates. In the current study, we screened a DNA panel composing 44 ethnically diverse individuals and found nine nonsynonymous and four synonymous coding-region SNPs in human PEPT1. Then, we studied the functional relevance of the nonsynonymous cSNPs by using a heterologous expression system.
Our sequencing data are compared with preliminary data on PEPT1 from PMT project (Table 4) . Although both DNA panels studied in our study and PMT project were from Coriell Institute, our panel, which is smaller in sample size, is not a subset of the DNA samples in PMT project. The two most common nonsynonymous cSNPs, S117N and G419A, were identified in both studies with similar allelic frequency. In addition, three other nonsynonymous cSNPs (V122M, V450I, and T451N) and all four synonymous cSNPs identified in our study were also found in the PMT project, although with different frequencies. However, all low-frequency cSNPs (Յ0.4%, occurring in one or two chromosomes in the total of 247 subjects) in PMT dataset were not found in our study. The converse is true for three low-frequency cSNPs, including T114I, R459C, and P586L (Յ1.1%), identified in our study, each of which occurred once in the total of 88 chromosomes. It seems that the smaller sample size of 44 individuals screened in our study is sufficient to identify major PEPT1 variants, because all of the relatively highfrequency cSNPs found in our study matched well with the results from the PMT project. However, surprisingly, three low-frequency nonsynonymous cSNPs (T114I, R459C, and P586L) were found in our subjects, but not in PMT project. Furthermore, a resequencing effort on the individual DNA samples with these PEPT1 variations has ruled out the possibility of sequencing error.
When the transport function of the identified nine nonsynonymous variants was assessed in vitro in comparison with the reference PEPT1 gene, all variants, including P586L, similar to the reference, possessed the higher uptake rate at the lower pH value (Fig. 5A ). This retained pH dependence on Gly-Sar uptake indicates that these codon changes seem not to occur in PEPT1 regions essential for proton cotransport. Kinetic studies revealed comparable K t values for GlySar uptake by all variants and the reference (Table 2) . To further assess whether this conserved substrate recognition can be seen with drug substrates, seven chemically diverse compounds, including ␤-lactams antibiotics (cefadroxil and cephalexin), angiotensin-converting enzyme inhibitors (captopril and enalapril), peptidomimetic drugs (bestatin), and nonpeptidic substrates (L-DOPA and 5-aminoleuvulinic acid), were selected. A single concentration (10 mM) for all drug substrates was chosen in the uptake inhibition study. At this tested concentration, the inhibitory effect of each compound could be roughly categorized as relatively high, medium, and low (see Results). Table 3 demonstrates that the inhibition ranking of each drug substrate observed in the reference PEPT1 was, by and large, similarly seen among all the variants. Therefore, collectively, these results suggest that all variants likely retain a substrate-recognition/binding pocket similar to the reference PEPT1.
One interesting finding in the study was the reduced uptake capacity of variant P586L. This variant retains pHdependent uptake, but with significantly reduced capacity. Kinetic studies revealed that P586L has similar K t to Gly-Sar as the reference and other variants, but with a transport capacity 10-fold less as measured by V max . In addition, the inhibitory effect by the selected drug substrates on Gly-Sar uptake by P586L was similar to that observed with the other variants. Western blot analysis on whole cell lysate (Fig. 5B ) demonstrated that P586L was expressed at a much lower level in comparison with the reference in transfected HeLa cells. Further immunocytochemical studies confirmed that membrane expression level of P586L was indeed lower than that of the reference. Therefore, the lower transport capacity (V max ) observed in P586L is likely the result of the lower transporter density on cell membrane, and not due to intrinsic changes in transport function. Because protein expression is controlled by both transcriptional and translational/posttranslational mechanisms, we performed a real-time PCR study to assess whether there was any alteration on mRNA expression level of each variant, which may account for the Ref  T114I  S117N  V122M  V416L  G419A  V450I  T451N  R459C  P586L   Glycine  4  1  1  0  1  0  2  0  0  5  Gly-Sar  96  93  95  94  95  94  93  94  95  96  Bestatin  99  96  95  97  96  94  96  94  96  96  ALA  89  90  87  88  87  87  85  84  86  76  Enalapril  87  93  89  95  92  91  94  90  92  90  Cefadroxil  73  76  62  70  65  70  72  69  66  61  Captopril  61  64  52  64  53  52  57  49  50  41  Cephalexin  53  38  48  40  39  31  35  34  29 jpet.aspetjournals.org changes on protein expression level (especially for P586L). Results (Fig. 4) suggested that all variants (including P586L) showed slightly higher mRNA level than the reference gene in the transient transfected cell system. Therefore, the significant reduction of P586L protein expression level seems not to be attributed to variations on gene transcription, but mainly due to alterations occurring post-transcriptionally. Given that Pro 586 is located on the putative membrane boundary of the transmembrane (TM) domain and could be an essential residue for ␣-helix packing of TM domain (Brandl and Deber, 1986) , we propose that substitution of proline with leucine at position 586 may have profound effect on protein stability or translational control, which leads to low protein expression level on the cell membrane. Experiments to determine the effect of P586L on post-transcriptional events are beyond the scope of this study and are the subject of future work.
When using site-directed mutagenesis to study protein structure-function relationships, it is assumed that important amino acids are conserved in the protein family and changes in conserved residues should affect protein function. Similarly, this reasoning should stand when it comes to determining whether a nonsynonymous SNP of a given transporter can alter transport function and lead to a functional consequence. As shown in Fig. 3 , we created sequence alignments for partial regions in hPEPT1 containing the nine cSNPs and sequences from six animal species and human PEPT2. Some of the SNPs resulted in replacement of a conserved amino acid by a different amino acid present in another species in the same position (i.e., S117N and T451N). Gly 419 was not conserved across species, whereas the substituted alanine is observed in rat and mouse PEPT1. Based on this alignment, we expected that these three cSNPs (S117N, T451N, and G419A) should be functionally neutral, whereas the other cSNPs occurring at conserved positions would have a greater probability of resulting in a functional consequence, depending on the type of substituting residue. For example, P586L may have altered function, because Pro 586 is in an evolutionarily conserved region, and the substituting Leu is structurally different from Pro. Recently, a computational method was proposed to predict the cSNPs that might have a functional consequence. This program, Sorting Intolerant from Tolerant (Ng and Henikoff, 2002) , is actually a sequence homology based tool that evaluates whether amino acid changes are conserved within the protein family to predict which cSNPs would affect protein function. The Sorting Intolerant from Tolerant program predicted that most PEPT1 cSNPs identified were tolerated mutations, except for P586L (data not shown). Not surprisingly, our experimental results on P586L concurred with the prediction from this sequence homology based analysis.
Despite the efforts to elucidate the structure-function relationship of PEPT1, the exact PEPT1 protein domains important for proton coupling and substrate translocation remain elusive in the absence of a high-resolution threedimensional X-ray structure (Zhang et al., 2002) . To date, some amino acid residues or domains in PEPT1 have been revealed functionally important, and the results in the present study are largely compatible with those earlier findings: 1) Previous studies on PEPT1 and PEPT2 chimeras (Doring et al., 1996) suggested that the large extracellular loop between TM9 and TM10 is not essential for phenotypical characteristics of transporter function. This observation is in good agreement with our results: five cSNPs located on this loop have little influence on transporter function in terms of pH dependence, substrate uptake kinetics, and inhibition specificity. 2) Previous site-directed mutagenesis studies on human PEPT1 have revealed five functionally important conserved residues, which are all located in putative TM domains. Specifically, two histidine residues, i.e., His 57 and His 121 (Chen et al., 2000) , are on TM2 and TM4, respectively; Tyr 167 is on TM5 Yeung et al., 1998 ); Try 294 is on TM7, and Glu 595 is on TM10 . When human PEPT1 was mutated at each of these sites, transport function was lost or significantly diminished. In addition to identification of those functionally important residues in PEPT1, it has been proposed that the N-terminal one-half including TM7, TM8, and TM9 is the region of PEPT1 responsible for proton and substrate recognition (Doring et al., 1996; Fei et al., 1998; Terada et al., 2000) , and a recent study with cysteine mutagenesis on PEPT1 revealed that TM5 may be part of the substrate translocation pathway (Kulkarni et al., 2003) . Additionally, it has been speculated that the C-terminal region, although not directly involved in substrate recognition and binding, may be important for either protein trafficking or functional regulation (Doring et al., 1996) . Located on the membrane boundary of TM10 in C-terminal portion of PEPT1, Pro 586 was shown not to be important for protein function in terms of pH-dependent uptake, Gly-Sar affinity, and inhibitor specificity, because P586L behaved similarly to the reference gene with respect to these parameters. However, Pro 586 seemed important in determining PEPT1 expression level in the membrane. Coincidentally, the Ala-substituted mutant on another conserved residue in the TM10, Glu 595 , retained the K t value similar to the wild-type PEPT1, but it had significantly reduced transport capacity (V max ) in transfected human embryonic kidney cells . Although no experiment was carried out to assess the expression level of E595A, we speculate, in the context of the present study, that the low transport capacity (V max ) of E595A may be associated with lower incorporation of the protein in the membrane. Together, these results provide supporting evidence for the concept (Doring et al., 1996) regarding the potential role of C-terminal to PEPT1 function, i.e., regulating transporter expression level. Further analyses are required to determine how these residues in the C-terminal region of PEPT1 modulate the expression level of PEPT1.
Although P586L seems to be associated with a decrease in V max in transfected HeLa cells, we speculate that the reduction of uptake capacity in vitro may not be consequential in vivo, given that PEPT1 is expressed at a high level along the gastrointestinal tract (Ganapathy and Leibach, 1996) . The fact that no mutation identified in the studied subjects that resulted in complete loss of hPEPT1 function may reflect the strong selection and evolutionary pressure on this important mammalian peptide transporter, which has counterparts in bacteria, yeast, fungi, plants, and invertebrate and vertebrate animals. Therefore, the maintenance of appropriate di/tripeptide cellular uptake seems essential for the well being of all living creatures.
In this study, we reported the identification and in vitro functional characterization of human PEPT1 variants. Analyses of these cSNPs revealed that the mutations seem to be functionally neutral except for P586L, which maintained a similar affinity for Gly-Sar and drug substrates as the other variants but had reduced protein expression in transfected HeLa cells. These data suggest that the C-terminal region of PEPT1 (where Pro 586 resides) seems to be involved in regulation on PEPT1 expression, which is consistent with previous studies. However, the P586L allele seems to be a rare variant (found in one chromosome of 44 subjects in our study, but not found in another larger group of subjects, i.e., 247 individuals in PMT study) and therefore would have minimal impact on oral absorption of PEPT1 drug substrates. In conclusion, human PEPT1 transport functionality seems to be highly conserved, and PEPT1 polymorphisms are not expected to be a significant factor with respect to intersubject variability in oral absorption of its drug substrates.
